| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780638 | Gynecologic Oncology | 2018 | 5 Pages |
Abstract
Apatinib 500Â mg daily p.o. is a feasible treatment in patients with recurrent, platinum-resistant, pretreated EOC. Multi-center prospective studies enrolling more patients are needed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Mingming Miao, Guanming Deng, Sujuan Luo, Jiajia Zhou, Le Chen, Jun Yang, Jie He, Junjun Li, Jing Yao, Shanmei Tan, Jie Tang,